Details of Drug

Drug General Information (ID: D1707)
Drug Name	Vorinostat
Drug Type	Small molecule
Drug Synonymous	NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor) Click to Show/Hide
Disease Class	2B01: Mycosis fungoides
Therapeutic Class	Antineoplastics
Structure
Structure	3D Structure		2D Structure
Formula	C14H20N2O3
InChI	1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
InChIKey	WAEXFXRVDQXREF-UHFFFAOYSA-N
Canonical SMILES	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
External Link
	Pubchem ID	5311
	CAS Number	149647-78-9
	CHEBI ID	45716
	TTD ID	D0E7PQ
	INTEDE ID	DR1710
	VARIDT ID	DR00769

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM043 Additive immunosuppressive effects BM047 Additive thrombogenic effects BM050 Increased risk of bleeding BM076 Increased risk of prolong QT interval BM086 Antagonize the effect of antidiabetic agents BM089 Antagonize the effect of antihypertensive agents BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Vorinostat
Pharmacodynamic additive effects
	Additive immunosuppressive effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1855		Palifermin	NA	NA	Moderate		Inter Info	[26]
	Additive thrombogenic effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1569		Thalidomide	C13H10N2O4	5426	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]
	Increased risk of bleeding					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1677		Valproic acid	C8H16O2	3121	Major		Inter Info	[17], [18], [19]
D0087		Anisindione	C16H12O3	2197	Moderate		Inter Info	[23], [24], [19]
D0481		Dicoumarol	C19H12O6	54676038	Moderate		Inter Info	[23], [24], [19]
D1711		Warfarin	C19H16O4	54678486	Moderate		Inter Info	[23], [24], [19]
	Increased risk of prolong QT interval					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0937		Lisdexamfetamine	C15H25N3O	11597698	Moderate		Inter Info	[25]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[27]
Pharmacodynamic antagonistic effects
	Antagonize the effect of antidiabetic agents					Drug Num: 41
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0009		Acarbose	C25H43NO18	41774	Moderate		Inter Info	[20], [21], [22]
D0013		Acetohexamide	C15H20N2O4S	1989	Moderate		Inter Info	[20], [21], [22]
D0325		Chlorpropamide	C10H13ClN2O3S	2727	Moderate		Inter Info	[20], [21], [22]
D1784		Exenatide	C184H282N50O60S	45588096	Moderate		Inter Info	[20], [21], [22]
D0727		Glimepiride	C24H34N4O5S	3476	Moderate		Inter Info	[20], [21], [22]
D0728		Glipizide	C21H27N5O4S	3478	Moderate		Inter Info	[20], [21], [22]
D0730		Glyburide	C23H28ClN3O5S	3488	Moderate		Inter Info	[20], [21], [22]
D0807		Insulin aspart (aspart protamine)	C256H381N65O79S6	118984445	Moderate		Inter Info	[20], [21], [22]
D0808		Insulin aspart (aspart)	C256H381N65O79S6	118984445	Moderate		Inter Info	[20], [21], [22]
D0810		Insulin detemir	C267H402N64O76S6	16137271	Moderate		Inter Info	[20], [21], [22]
D0811		Insulin glargine	C267H404N72O78S6	118984454	Moderate		Inter Info	[20], [21], [22]
D0812		Insulin glulisine	C258H384N64O78S6	16136701	Moderate		Inter Info	[20], [21], [22]
D0813		Insulin human	C257H383N65O77S6	118984375	Moderate		Inter Info	[20], [21], [22]
D0814		Insulin human (inhalation, rapid acting)	C257H383N65O77S6	118984375	Moderate		Inter Info	[20], [21], [22]
D0815		Insulin human (isophane)	C257H383N65O77S6	118984375	Moderate		Inter Info	[20], [21], [22]
D0816		Insulin human (regular)	C257H383N65O77S6	118984375	Moderate		Inter Info	[20], [21], [22]
D0817		Insulin human (zinc extended)	C257H383N65O77S6	118984375	Moderate		Inter Info	[20], [21], [22]
D0818		Insulin human (zinc)	C257H383N65O77S6	118984375	Moderate		Inter Info	[20], [21], [22]
D0819		Insulin lispro	C257H389N65O77S6	16132438	Moderate		Inter Info	[20], [21], [22]
D0820		Insulin lispro (protamine)	C257H389N65O77S6	16132438	Moderate		Inter Info	[20], [21], [22]
D1015		Metformin	C4H11N5	4091	Moderate		Inter Info	[20], [21], [22]
D1064		Miglitol	C8H17NO5	441314	Moderate		Inter Info	[20], [21], [22]
D1112		Nateglinide	C19H27NO3	5311309	Moderate		Inter Info	[20], [21], [22]
D1294		Pioglitazone	C19H20N2O3S	4829	Moderate		Inter Info	[20], [21], [22]
D1326		Pramlintide	C171H267N51O53S2	70691388	Moderate		Inter Info	[20], [21], [22]
D1392		Repaglinide	C27H36N2O4	65981	Moderate		Inter Info	[20], [21], [22]
D1429		Rosiglitazone	C18H19N3O3S	77999	Moderate		Inter Info	[20], [21], [22]
D1477		Sitagliptin	C16H15F6N5O	4369359	Moderate		Inter Info	[20], [21], [22]
D1601		Tolazamide	C14H21N3O3S	5503	Moderate		Inter Info	[20], [21], [22]
D1603		Tolbutamide	C12H18N2O3S	5505	Moderate		Inter Info	[20], [21], [22]
D1652		Troglitazone	C24H27NO5S	5591	Moderate		Inter Info	[20], [21], [22]
D0029		Albiglutide	C148H224N40O45	145994868	Moderate		Inter Info	[20], [21], [22]
D0042		Alogliptin	C18H21N5O2	11450633	Moderate		Inter Info	[20], [21], [22]
D0245		Canagliflozin	C24H25FO5S	24812758	Moderate		Inter Info	[20], [21], [22]
D0418		Dapagliflozin	C21H25ClO6	9887712	Moderate		Inter Info	[20], [21], [22]
D0565		Empagliflozin	C23H27ClO7	11949646	Moderate		Inter Info	[20], [21], [22]
D0809		Insulin degludec	C274H411N65O81S6	118984462	Moderate		Inter Info	[20], [21], [22]
D0930		Linagliptin	C25H28N8O2	10096344	Moderate		Inter Info	[20], [21], [22]
D0936		Liraglutide	C172H265N43O51	16134956	Moderate		Inter Info	[20], [21], [22]
D0941		Lixisenatide	C215H347N61O65S	90472060	Moderate		Inter Info	[20], [21], [22]
D1449		Saxagliptin	C18H25N3O2	11243969	Moderate		Inter Info	[20], [21], [22]
	Antagonize the effect of antihypertensive agents					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1779		Dulaglutide	NA	NA	Moderate		Inter Info	[20], [21], [22]
D1782		Ertugliflozin	C22H25ClO7	44814423	Moderate		Inter Info	[20], [21], [22]
D1887		Semaglutide	C187H291N45O59	56843331	Moderate		Inter Info	[20], [21], [22]

References
1	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
2	Bennett CL, Schumock GT, Desai AA, et al "Thalidomide-associated deep vein thrombosis and pulmonary embolism." Am J Med 113 (2002): 603-6. [PMID: 12459408]
3	Cavo M, Zamagni E, Cellini C, et al. "Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy." Blood 100 (2002): 2272-3. [PMID: 12229885]
4	Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A "Thalidomide and venous thrombosis." Ann Intern Med 136 (2002): 711. [PMID: 11992318]
5	Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
6	Fine HA, Wen PY, Maher EA, et al. "Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas." J Clin Oncol 21 (2003): 2299-304. [PMID: 12805330]
7	Lee CK, Barlogie B, Munshi N, et al "DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma." J Clin Oncol 21 (2003): 2732-9. [PMID: 12860952]
8	Osman K, Comenzo R, Rajkumar SV "Deep venous thrombosis and thalidomide therapy for multiple myeloma." N Engl J Med 344 (2001): 1951-2. [PMID: 11419443]
9	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
10	Rajkumar SV, Hayman S, Gertz MA, et al. "Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma." J Clin Oncol 20 (2002): 4319-23. [PMID: 12409330]
11	Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J "Thromboembolic events during treatment with thalidomide." Blood 99 (2002): 4247-8. [PMID: 12043695]
12	Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R "Thalidomide alone or with dexamethasone for previously untreated multiple myeloma." J Clin Oncol 21 (2003): 16-9. [PMID: 12506164]
13	Zangari M, Anaissie E, Barlogie B, et al "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy." Blood 98 (2001): 1614-5. [PMID: 11520815]
14	Zangari M, Barlogie B, Anaissie E, et al "Deep vein thrombosis in patients with mutiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation." Br J Haematol 126 (2004): 715-21. [PMID: 15327525]
15	Zangari M, Siegel E, Barlogie B, et al "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy." Blood 100 (2002): 1168-71. [PMID: 12149193]
16	Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM "A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma." Cancer 95 (2002): 1629-36. [PMID: 12365009]
17	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
18	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
19	Product Information. Zolinza (vorinostat). Merck &amp Company Inc, West Point, PA.
20	Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4. [PMID: 4381950]
21	Product Information. Dymelor (acetohexamide) Lilly, Eli and Company, Indianapolis, IN.
22	Product Information. Thorazine (chlorpromazine). SmithKline Beecham, Philadelphia, PA.
23	Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36. [PMID: 14769198]
24	Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
25	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26	Product Information. Kepivance (palifermin). Shire US Inc, Florence, KY.
27	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence